Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 29;71(17):606-608.
doi: 10.15585/mmwr.mm7117e3.

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022

Kristie E N Clarke, Jefferson M Jones, Yangyang Deng, Elise Nycz, Adam Lee, Ronaldo Iachan, Adi V Gundlapalli, Aron J Hall, Adam MacNeil

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022

Kristie E N Clarke et al. MMWR Morb Mortal Wkly Rep. .

Abstract

In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Seroprevalence of infection-induced SARS-CoV-2 antibodies, by age group — United States, September 2021–February 2022 * Error bars represent 95% CIs at each time point.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Battaglia MP, Hoaglin DC, Frankel MR. Practical considerations in raking survey data. Surv Pract 2009;2:1–10. 10.29115/SP-2009-0019 - DOI
    1. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979;7:1–26. http://www.jstor.org/stable/2958830 10.1214/aos/1176344552 - DOI
    1. Lu P, Kong D, Shelley M. Risk perception, preventive behavior, and medical care avoidance among American older adults during the COVID-19 pandemic. J Aging Health 2021;33:577–84. 10.1177/08982643211002084 - DOI - PubMed
    1. Shi DS, Whitaker M, Marks KJ, et al. Hospitalizations of children aged 5–11 years with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 2020–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:574–81. 10.15585/mmwr.mm7116e1 - DOI - PMC - PubMed
    1. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022;399:5–11. 10.1016/S0140-6736(22)00152-0 - DOI - PMC - PubMed

Substances